{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T00:13:14Z","timestamp":1777162394387,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,4,11]],"date-time":"2017-04-11T00:00:00Z","timestamp":1491868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1038\/bjc.2017.91","type":"journal-article","created":{"date-parts":[[2017,4,11]],"date-time":"2017-04-11T20:02:23Z","timestamp":1491940943000},"page":"1312-1317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer"],"prefix":"10.1038","volume":"116","author":[{"given":"A","family":"Janssen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C P M","family":"Verkleij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"van der Vlist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R H J","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H J","family":"Bloemendal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"ter Heine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,11]]},"reference":[{"key":"BFbjc201791_CR1","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NH (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48: 303\u2013332.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"BFbjc201791_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2133\/dmpk.24.25","volume":"24","author":"BJ Anderson","year":"2009","unstructured":"Anderson BJ, Holford NH (2009) Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 24: 25\u201336.","journal-title":"Drug Metab Pharmacokinet"},{"key":"BFbjc201791_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13: 143\u2013151.","journal-title":"AAPS J"},{"key":"BFbjc201791_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/clpt.2014.12","volume":"95","author":"S Bins","year":"2014","unstructured":"Bins S, Ratain MJ, Mathijssen RH (2014) Conventional dosing of anticancer agents: precisely wrong or just inaccurate? Clin Pharmacol Ther 95: 361\u2013364.","journal-title":"Clin Pharmacol Ther"},{"key":"BFbjc201791_CR5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2217\/fon.13.256","volume":"10","author":"S Bracarda","year":"2014","unstructured":"Bracarda S, Gernone A, Gasparro D, Marchetti P, Ronzoni M, Bortolus R, Fratino L, Basso U, Mazzanti R, Messina C, Tucci M, Boccardo F, Carteni G, Pinto C, Fornarini G, Mattioli R, Procopio G, Chiuri V, Scotto T, Dondi D, Di Lorenzo G (2014) Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. Future Oncol 10: 975\u2013983.","journal-title":"Future Oncol"},{"key":"BFbjc201791_CR6","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s00277-003-0727-9","volume":"83","author":"O Brosteanu","year":"2004","unstructured":"Brosteanu O, Hasenclever D, Loeffler M, Diehl V Group German Hodgkin's Lymphoma Study (2004) Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease. Ann Hematol 83: 176\u2013182.","journal-title":"Ann Hematol"},{"key":"BFbjc201791_CR7","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/bjc.2012.357","volume":"107","author":"E Chatelut","year":"2012","unstructured":"Chatelut E, White-Koning ML, Mathijssen RH, Puisset F, Baker SD, Sparreboom A (2012) Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. Br J Cancer 107: 1100\u20131106.","journal-title":"Br J Cancer"},{"key":"BFbjc201791_CR8","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO Tropic Investigators (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376: 1147\u20131154.","journal-title":"Lancet"},{"key":"BFbjc201791_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jpba.2011.10.010","volume":"59","author":"P de Bruijn","year":"2012","unstructured":"de Bruijn P, de Graan AJ, Nieuweboer A, Mathijssen RH, Lam MH, de Wit R, Wiemer EA, Loos WJ (2012) Quantification of cabazitaxel in human plasma by liquid chromatography\/triple-quadrupole mass spectrometry: a practical solution for non-specific binding. J Pharm Biomed Anal 59: 117\u2013122.","journal-title":"J Pharm Biomed Anal"},{"key":"BFbjc201791_CR10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2165\/00003088-200544020-00002","volume":"44","author":"ME de Jonge","year":"2005","unstructured":"de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH (2005) Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review. Clin Pharmacokinet 44: 147\u2013173.","journal-title":"Clin Pharmacokinet"},{"key":"BFbjc201791_CR11","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2165\/00003088-199937060-00004","volume":"37","author":"SN de Wildt","year":"1999","unstructured":"de Wildt SN, Kearns GL, Leeder JS, van den Anker JN (1999) Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 37: 485\u2013505.","journal-title":"Clin Pharmacokinet"},{"key":"BFbjc201791_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00280-013-2322-7","volume":"73","author":"D de Wit","year":"2014","unstructured":"de Wit D, Gelderblom H, Sparreboom A, den Hartigh J, den Hollander M, Konig-Quartel JM, Hessing T, Guchelaar HJ, van Erp NP (2014) Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer. Cancer Chemother Pharmacol 73: 87\u201396.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFbjc201791_CR13","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(05)70255-2","volume":"6","author":"M Di Maio","year":"2005","unstructured":"Di Maio M, Gridelli C, Gallo C, Shepherd F, Piantedosi FV, Cigolari S, Manzione L, Illiano A, Barbera S, Robbiati SF, Frontini L, Piazza E, Ianniello GP, Veltri E, Castiglione F, Rosetti F, Gebbia V, Seymour L, Chiodini P, Perrone F (2005) Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 6: 669\u2013677.","journal-title":"Lancet Oncol"},{"key":"BFbjc201791_CR14","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/archinte.1916.00080130010002","volume":"XVII","author":"D du Bois","year":"1916","unstructured":"du Bois D, du Bois EF (1916) Clinical calorimetry: tenth paper a formula to estimate the approximate surface area if height and weight be known. Arch Intern Med XVII: 863\u2013871.","journal-title":"Arch Intern Med"},{"key":"BFbjc201791_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1158\/1535-7163.MCT-14-0155","volume":"14","author":"GE Duran","year":"2015","unstructured":"Duran GE, Wang YC, Francisco EB, Rose JC, Martinez FJ, Coller J, Brassard D, Vrignaud P, Sikic BI (2015) Mechanisms of resistance to cabazitaxel. Mol Cancer Ther 14: 193\u2013201.","journal-title":"Mol Cancer Ther"},{"key":"BFbjc201791_CR16","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00280-012-2058-9","volume":"71","author":"GM Ferron","year":"2013","unstructured":"Ferron GM, Dai Y, Semiond D (2013) Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 71: 681\u2013692.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFbjc201791_CR17","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1200\/JCO.2002.01.025","volume":"20","author":"BC Goh","year":"2002","unstructured":"Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, Schuetz E, Lim R, Lim HL, Ong AB, Lee HS (2002) Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 20: 3683\u20133690.","journal-title":"J Clin Oncol"},{"key":"BFbjc201791_CR18","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.eururo.2012.08.058","volume":"63","author":"A Heidenreich","year":"2013","unstructured":"Heidenreich A, Scholz HJ, Rogenhofer S, Arsov C, Retz M, Muller SC, Albers P, Gschwend J, Wirth M, Steiner U, Miller K, Heinrich E, Trojan L, Volkmer B, Honecker F, Bokemeyer C, Keck B, Otremba B, Ecstein-Fraisse E, Pfister D (2013) Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Eur Urol 63: 977\u2013982.","journal-title":"Eur Urol"},{"key":"BFbjc201791_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1208\/s12248-012-9320-2","volume":"14","author":"M Joerger","year":"2012","unstructured":"Joerger M (2012) Covariate pharmacokinetic model building in oncology and its potential clinical relevance. AAPS J 14: 119\u2013132.","journal-title":"AAPS J"},{"key":"BFbjc201791_CR20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s40880-015-0003-0","volume":"34","author":"RJ Kathawala","year":"2015","unstructured":"Kathawala RJ, Wang YJ, Shukla S, Zhang YK, Alqahtani S, Kaddoumi A, Ambudkar SV, Ashby CR Jr, Chen ZS (2015) ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) are not primary resistance factors for cabazitaxel. Chin J Cancer 34: 115\u2013120.","journal-title":"Chin J Cancer"},{"key":"BFbjc201791_CR21","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00228-010-0878-2","volume":"66","author":"S Katzenmaier","year":"2010","unstructured":"Katzenmaier S, Markert C, Mikus G (2010) Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam. Eur J Clin Pharmacol 66: 1137\u20131141.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFbjc201791_CR22","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1038\/psp.2013.24","volume":"2","author":"RJ Keizer","year":"2013","unstructured":"Keizer RJ, Karlsson MO, Hooker A (2013) Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol 2: e50.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"BFbjc201791_CR23","doi-asserted-by":"publisher","first-page":"7398","DOI":"10.1158\/1078-0432.CCR-05-0520","volume":"11","author":"ER Lepper","year":"2005","unstructured":"Lepper ER, Baker SD, Permenter M, Ries N, van Schaik RH, Schenk PW, Price DK, Ahn D, Smith NF, Cusatis G, Ingersoll RG, Bates SE, Mathijssen RH, Verweij J, Figg WD, Sparreboom A (2005) Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin Cancer Res 11: 7398\u20137404.","journal-title":"Clin Cancer Res"},{"key":"BFbjc201791_CR24","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1093\/jnci\/djh298","volume":"96","author":"RH Mathijssen","year":"2004","unstructured":"Mathijssen RH, de Jong FA, van Schaik RH, Lepper ER, Friberg LE, Rietveld T, de Bruijn P, Graveland WJ, Figg WD, Verweij J, Sparreboom A (2004) Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 96: 1585\u20131592.","journal-title":"J Natl Cancer Inst"},{"key":"BFbjc201791_CR25","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nrclinonc.2014.40","volume":"11","author":"RH Mathijssen","year":"2014","unstructured":"Mathijssen RH, Sparreboom A, Verweij J (2014) Determining the optimal dose in the development of anticancer agents. Nat Rev Clin Oncol 11: 272\u2013281.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFbjc201791_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ejca.2005.08.035","volume":"42","author":"RH Mathijssen","year":"2006","unstructured":"Mathijssen RH, van Schaik RH (2006) Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment. Eur J Cancer 42: 141\u2013148.","journal-title":"Eur J Cancer"},{"key":"BFbjc201791_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejca.2015.12.009","volume":"56","author":"A Meisel","year":"2016","unstructured":"Meisel A, von Felten S, Vogt DR, Liewen H, de Wit R, de Bono J, Sartor O, Stenner-Liewen F (2016) Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial. Eur J Cancer 56: 93\u2013100.","journal-title":"Eur J Cancer"},{"key":"BFbjc201791_CR28","unstructured":"NDA (2013) 201023 Review \n                    http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/201023s000ClinPharmR.pdf\n                    \n                  ."},{"issue":"7","key":"BFbjc201791_CR29","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1158\/1078-0432.CCR-16-2110","volume":"23","author":"Annemieke J.M. Nieuweboer","year":"2016","unstructured":"Nieuweboer AJ, de Graan AM, Hamberg P, Bins S, van Soest RJ, van Alphen RJ, Bergman AM, Beeker A, van Halteren H, Ten Tije A, Zuetenhorst H, van der Meer N, Chitu D, de Wit R, Mathijssen RH (2016) Effects of budesonide on cabazitaxel pharmacokinetics and cabazitaxel-induced diarrhea: a randomized, open-label multicenter phase II study. Clin Cancer Res e-pub ahead of print 4 October 2016; doi:10.1158\/1078-0432.CCR-16-2110.","journal-title":"Clinical Cancer Research"},{"key":"BFbjc201791_CR30","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1097\/FPC.0b013e32833225e7","volume":"19","author":"B Oneda","year":"2009","unstructured":"Oneda B, Crettol S, Jaquenoud Sirot E, Bochud M, Ansermot N, Eap CB (2009) The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet Genomics 19: 877\u2013883.","journal-title":"Pharmacogenet Genomics"},{"key":"BFbjc201791_CR31","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.ctrv.2011.12.003","volume":"38","author":"FL Opdam","year":"2012","unstructured":"Opdam FL, Gelderblom H, Guchelaar HJ (2012) Phenotyping drug disposition in oncology. Cancer Treat Rev 38: 715\u2013725.","journal-title":"Cancer Treat Rev"},{"key":"BFbjc201791_CR32","first-page":"387","volume":"33","author":"DE Oprea-Lager","year":"2013","unstructured":"Oprea-Lager DE, Bijnsdorp IV, Moorselaar VAN, Van Den Eertwegh RJ, AJ, Hoekstra OS, Geldof AA (2013) ABCC4 decreases docetaxel and not cabazitaxel efficacy in prostate cancer cells in vitro. Anticancer Res 33: 387\u2013391.","journal-title":"Anticancer Res"},{"key":"BFbjc201791_CR33","first-page":"853","volume":"18","author":"D Pinkel","year":"1958","unstructured":"Pinkel D (1958) The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 18: 853\u2013856.","journal-title":"Cancer Res"},{"key":"BFbjc201791_CR34","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/CAD.0000000000000185","volume":"26","author":"L Ridoux","year":"2015","unstructured":"Ridoux L, Semiond DR, Vincent C, Fontaine H, Mauriac C, Sanderink GJ, Oprea C, Kelly L, Clive S (2015) A phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors. Anticancer Drugs 26: 350\u2013358.","journal-title":"Anticancer Drugs"},{"key":"BFbjc201791_CR35","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO (2009) Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J 11: 558\u2013569.","journal-title":"AAPS J"},{"key":"BFbjc201791_CR36","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1021\/acs.molpharmaceut.5b00470","volume":"12","author":"SC Tang","year":"2015","unstructured":"Tang SC, Kort A, Cheung KL, Rosing H, Fukami T, Durmus S, Wagenaar E, Hendrikx JJ, Nakajima M, van Vlijmen BJ, Beijnen JH, Schinkel AH (2015) P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain disposition and oral availability of the novel taxane cabazitaxel (Jevtana) in mice. Mol Pharm 12: 3714\u20133723.","journal-title":"Mol Pharm"},{"key":"BFbjc201791_CR37","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nrc1629","volume":"5","author":"SD Undevia","year":"2005","unstructured":"Undevia SD, Gomez-Abuin G, Ratain MJ (2005) Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 5: 447\u2013458.","journal-title":"Nat Rev Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc201791.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201791","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bjc.2017.91","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201791.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:41:53Z","timestamp":1684417313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc201791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,11]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["BFbjc201791"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2017.91","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,11]]},"assertion":[{"value":"17 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RHJ Mathijssen receives funding by Sanofi for research projects. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}